Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Lung Cancer

  Free Subscription


16.03.2020

1 AJR Am J Roentgenol
1 Ann Thorac Surg
2 Arch Bronconeumol
1 Arch Pathol Lab Med
1 BMC Cancer
2 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Res
1 Cancer Sci
1 Clin Cancer Res
1 Clin Lung Cancer
1 Clin Nucl Med
2 Eur J Cardiothorac Surg
1 J Cancer Res Clin Oncol
1 J Clin Oncol
3 J Thorac Oncol
3 JAMA Oncol
1 Lancet Respir Med
1 Lung Cancer (Auckl)
1 Mol Carcinog
1 Oncogene
4 Oncologist


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. MA Y, Byrne SC, Gange C Jr, Hunsaker AR, et al
    Radiologic-Pathologic Correlation for Nondiagnostic CT-Guided Lung Biopsies Performed for the Evaluation of Lung Cancer.
    AJR Am J Roentgenol. 2020 Mar 11:1-5. doi: 10.2214/AJR.19.22244.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  2. KHORFAN R, Kruser TJ, Coughlin JM, Bharat A, et al
    Survival of Primary SBRT Compared to Surgery for Operable Stage I/II Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2020 Mar 5. pii: S0003-4975(20)30341.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  3. GONZALEZ-MARRON A, Martin-Sanchez JC, Garcia-Alemany F, Martinez-Martin E, et al
    Primary and Secondary Prevention Strategies to Reduce the Impact of Lung Cancer in Women: Where Are We Now and Where Are We Going?
    Arch Bronconeumol. 2020 Mar 3. pii: S0300-2896(20)30054.
    PubMed     Text format    

  4. GARCIA-PACHON E, Padilla-Navas I
    The Lower Airway Microbiome and Lung Cancer.
    Arch Bronconeumol. 2020 Mar 3. pii: S0300-2896(20)30052.
    PubMed     Text format    


    Arch Pathol Lab Med

  5. PARRA ER, Jiang M, Machado-Rugolo J, Yaegashi LB, et al
    Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.
    Arch Pathol Lab Med. 2020 Mar 9. doi: 10.5858/arpa.2019-0419.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. TOZUKA T, Kitazono S, Sakamoto H, Yoshida H, et al
    Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
    BMC Cancer. 2020;20:207.
    PubMed     Text format     Abstract available


    Cancer

  7. LEE J, Kim HS, Lee B, Kim HK, et al
    Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32809.
    PubMed     Text format     Abstract available

  8. PASSARO A, Malapelle U, Attili I, de Marinis F, et al
    Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32810.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  9. KIM SJ, Jegal KH, Im JH, Park G, et al
    Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer.
    Cancer Chemother Pharmacol. 2020 Mar 11. pii: 10.1007/s00280-020-04043.
    PubMed     Text format     Abstract available


    Cancer Res

  10. ZONG D, Gu J, Cavalcante GC, Yao W, et al
    BRD4 levels determine the response of human lung cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1.
    Cancer Res. 2020 Mar 10. pii: 0008-5472.CAN-19-3674.
    PubMed     Text format     Abstract available


    Cancer Sci

  11. NISHIO M, Kato T, Niho S, Yamamoto N, et al
    Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Cancer Sci. 2020 Mar 11. doi: 10.1111/cas.14384.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  12. HSIAO TF, Wang CL, Wu YC, Feng HP, et al
    Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer.
    Clin Cancer Res. 2020 Mar 10. pii: 1078-0432.CCR-19-3972.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  13. O'NEILL RS, Mohd Zaki NI, Grant C, Napaki S, et al
    A Case of Non-Small-cell Lung Cancer in a Patient With Neurofibromatosis Type 1.
    Clin Lung Cancer. 2020 Feb 8. pii: S1525-7304(20)30019.
    PubMed     Text format    


    Clin Nucl Med

  14. ZHOU W, Dong H, Dong A
    Isolated Pancreatic Metastasis From Squamous Cell Lung Cancer Mimicking Primary Pancreatic Ductal Adenocarcinoma on FDG PET/CT.
    Clin Nucl Med. 2020 Mar 7. doi: 10.1097/RLU.0000000000002986.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  15. YUN JK, Bok JS, Lee GD, Kim HR, et al
    Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2020 Mar 10. pii: 5802580. doi: 10.1093.
    PubMed     Text format     Abstract available

  16. CHOI S, Park J
    Surgical outcomes and prognosis of non-small-cell lung cancer in patients with chronic lung diseases: a retrospective analysis.
    Eur J Cardiothorac Surg. 2020 Mar 12. pii: 5804139. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  17. NI Y, Ye X, Yang X, Huang G, et al
    Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis.
    J Cancer Res Clin Oncol. 2020 Mar 7. pii: 10.1007/s00432-020-03176.
    PubMed     Text format     Abstract available


    J Clin Oncol

  18. GADGEEL S, Rodriguez-Abreu D, Speranza G, Esteban E, et al
    Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 Mar 9:JCO1903136. doi: 10.1200/JCO.19.03136.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  19. ZHANG H, Huang Y, Xie C
    The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2.
    J Thorac Oncol. 2020 Mar 5. pii: S1556-0864(20)30191.
    PubMed     Text format    

  20. LI W, Liu Y, Li W, Chen L, et al
    Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in non-small cell lung cancer.
    J Thorac Oncol. 2020 Mar 6. pii: S1556-0864(20)30189.
    PubMed     Text format     Abstract available

  21. CAO P, Jeon J, Levy DT, Jayasekera J, et al
    Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States.
    J Thorac Oncol. 2020 Feb 27. pii: S1556-0864(20)30130.
    PubMed     Text format     Abstract available


    JAMA Oncol

  22. GAO C, Cai S, He Y
    Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Mar 12. pii: 2762581. doi: 10.1001/jamaoncol.2020.0059.
    PubMed     Text format    

  23. ARRIETA O, Ramirez-Tirado LA, Zatarain-Barron ZL
    Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2020 Mar 12. pii: 2762582. doi: 10.1001/jamaoncol.2020.0062.
    PubMed     Text format    

  24. OKAMOTO I, Nokihara H, Nomura S, Niho S, et al
    Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2020 Mar 12:e196828. doi: 10.1001/jamaoncol.2019.6828.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  25. KIRBY T
    Discovery of lung cancer after an injury on holiday.
    Lancet Respir Med. 2020 Mar 9. pii: S2213-2600(20)30113.
    PubMed     Text format    


    Lung Cancer (Auckl)

  26. MEHTA A, Saifi M, Batra U, Suryavanshi M, et al
    Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.
    Lung Cancer (Auckl). 2020;11:19-25.
    PubMed     Text format     Abstract available


    Mol Carcinog

  27. WANG Q, Yang G, Jiang Y, Luo M, et al
    XB130, regulated by miR-203, miR-219, and miR-4782-3p, mediates the proliferation and metastasis of non-small-cell lung cancer cells.
    Mol Carcinog. 2020 Mar 11. doi: 10.1002/mc.23180.
    PubMed     Text format     Abstract available


    Oncogene

  28. ARNAL-ESTAPE A, Cai WL, Albert AE, Zhao M, et al
    Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
    Oncogene. 2020 Mar 10. pii: 10.1038/s41388-020-1246.
    PubMed     Text format     Abstract available


    Oncologist

  29. CUFER T, Ciuleanu TE, Berzinec P, Galffy G, et al
    Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
    Oncologist. 2020;25:e598-e601.
    PubMed     Text format     Abstract available

  30. TAKAYAMA K, Ichiki M, Matsumoto T, Ebi N, et al
    Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:208-e417.
    PubMed     Text format     Abstract available

  31. AVANCINI A, Sartori G, Gkountakos A, Casali M, et al
    Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
    Oncologist. 2020;25:e555-e569.
    PubMed     Text format     Abstract available

  32. ASO M, Toi Y, Sugisaka J, Aiba T, et al
    Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:e536-e544.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: